SCHEMBL5224103

SCHEMBL5224103

CO[C@H]1CCN(Cc2ccc(-c3ccc(-c4noc(C)n4)cc3)cc2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.46
KCNH2 Q12809 2/20 0.46
GPR119 Q8TDV5 1/20 0.46
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MITF O75030 1/20 0.43
S1PR1 P21453 6/20 0.43
S1PR5 Q9H228 5/20 0.43
S1PR4 O95977 3/20 0.43
GRM2 Q14416 1/20 0.42
NAMPT P43490 1/20 0.42
MCHR1 Q99705 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.41
SPHK2 Q9NRA0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5224117 1.00 LTA4H (0.46) LTA4HKCNH2GPR119LMNAMAPT
SCHEMBL5928300 0.88 KCNH2 (0.43) LTA4HKCNH2GPR119LMNAMAPT
SCHEMBL5928296 0.88 KCNH2 (0.43) LTA4HKCNH2GPR119LMNAMAPT
SCHEMBL5222459 0.87 KCNH2 (0.43) KCNH2GPR119LMNAMAPTTSHR
SCHEMBL5221845 0.87 KCNH2 (0.43) KCNH2GPR119LMNAMAPTTSHR
SCHEMBL5221834 0.87 KCNH2 (0.43) KCNH2GPR119LMNAMAPTTSHR
SCHEMBL5223251 0.87 POLB (0.45) KCNH2GPR119LMNAMAPTTSHR
SCHEMBL5226220 0.87 POLB (0.45) KCNH2GPR119LMNAMAPTTSHR
SCHEMBL5223246 0.87 POLB (0.45) KCNH2GPR119LMNAMAPTTSHR
SCHEMBL5221218 0.84 KCNH2 (0.44) KCNH2GPR119LMNAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP claimed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO claimed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US claimed
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP disclosed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO disclosed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019998-A1 Histamine-3 receptor antagonist HRH3, HRH4, HRH2 LTA4H 491/4885KCNH2 909/4885GPR119 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.